Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian

Kejin Huang1, Jiashi Geng1, Jing Wang1

  • 1Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.

Cancer Science
|February 26, 2018
PubMed

Insights

Long non-coding RNA RP11-552M11.4 promotes epithelial ovarian cancer progression by increasing cell proliferation, migration, and invasion while inhibiting apoptosis. This lncRNA targets BRCA2, correlating with worse patient prognosis and advanced disease stages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epithelial ovarian cancer (EOC) remains a leading cause of cancer-related mortality.
  • The role of long non-coding RNAs (lncRNAs) in EOC pathogenesis is increasingly recognized.
  • Identifying novel molecular targets is crucial for improving EOC treatment strategies.

Purpose of the Study:

  • To investigate the functional role of lncRNA RP11-552M11.4 in epithelial ovarian cancer (EOC).
  • To determine the impact of lncRNA RP11-552M11.4 on cancer cell proliferation, apoptosis, migration, and invasion.
  • To elucidate the underlying molecular mechanism, including its interaction with target genes like BRCA2.

Main Methods:

  • Quantitative real-time PCR (qPCR) and Western blot for gene and protein expression analysis.
  • Cell Counting Kit-8 (CCK-8), Annexin V/propidium iodide (AV/PI) assays for proliferation and apoptosis.
  • Wound-healing and Matrigel invasion assays for migration and invasion.
  • Luciferase reporter assays and rescue experiments to confirm gene targeting.

Main Results:

  • LncRNA RP11-552M11.4 expression was significantly upregulated in EOC tumor tissues compared to adjacent tissues.
  • Elevated lncRNA RP11-552M11.4 levels correlated with higher pathological grade, advanced FIGO stage, and poorer overall survival.
  • Overexpression of lncRNA RP11-552M11.4 promoted proliferation, migration, and invasion, while inhibiting apoptosis in EOC cells (SKOV3, A-2780).
  • LncRNA RP11-552M11.4 exerted its effects by downregulating BRCA2 expression, as confirmed by rescue experiments and luciferase assays.

Conclusions:

  • LncRNA RP11-552M11.4 is an oncogenic lncRNA in EOC, associated with adverse clinical outcomes.
  • It promotes EOC progression by enhancing cell proliferation, migration, and invasion, and suppressing apoptosis.
  • Targeting lncRNA RP11-552M11.4 or its interaction with BRCA2 may represent a potential therapeutic strategy for EOC.

Related Concept Videos

Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
19.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cell Migration01:19

Cell Migration

Cell migration is a process by which the cells move from one location to another, playing an essential role in embryological development, repair and regeneration, immune response, and metastasis. Cells migrate in response to chemical or mechanical signals generated by specific organs or tissues. The overall mechanism includes three steps - polarization, protrusion, and release. Polarization involves the formation of a distinct cell front and rear, which determines the direction of movement.
6.7K
Cell Migration01:09

Cell Migration

Cell migration, the process by which cells move from one location to another, is essential for the proper development and viability of organisms throughout their life. When cells are not able to migrate properly to their ordained locations, various disorders may occur. For example, disruption in cell migration causes chronic inflammatory diseases such as arthritis.
18.9K